XyloCor closes $17M Series A round to develop gene therapy for refractory angina

The Philadelphia-based company has an IND open with the FDA and plans to begin its clinical trial in the first half of next year.

Article Source: XyloCor closes $17M Series A round to develop gene therapy for refractory angina.